A long-term safety and efficacy follow-on study in participants with transfusion dependent ß-thalassemia who have previously received GSK2696277 (autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene) and completed the TIGET-BTHAL study. - GSK2696277, P2b, beta-thalassemia patient safety follow-on to TIGET BTHAL study
A Phase I/II Study Evaluating Safety and Efficacy of Autologous Hematopoietic Stem Cells Genetically Modified With GLOBE Lentiviral Vector Encoding for the Human Beta-globin Gene for the Treatment of Patients Affected by Transfusion Dependent Beta-thalassemia
This is a phase I/II study evaluating safety and efficacy of autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene for the treatment of patients affected by transfusion dependent beta-thalassemia
100 项与 GSK-2696277 相关的临床结果
100 项与 GSK-2696277 相关的转化医学
100 项与 GSK-2696277 相关的专利(医药)
100 项与 GSK-2696277 相关的药物交易